On paper, substance use disorder treatment should be one of the most compelling investment opportunities in American healthcare. The demand is staggering and chronic. Over 48 million Americans meet the criteria for a substance use disorder in any given year. Opioid use disorder alone cost the United States an estimated $3.8 trillion in 2024. Overdose deaths, while finally showing modest declines from their pandemic-era peaks, remain at historically catastrophic levels. Federal and state funding continues to flow—opioid crisis settlement dollars, SAMHSA grants, Medicaid expansion—and the supply of treatment capacity falls dramatically short of need. By every conventional measure of healthcare market attractiveness, addiction treatment should be drawing institutional capital the way outpatient mental health and autism services have.
It isn't. And the reasons why tell you more about what makes a healthcare business actually investable than any amount of demand data ever could.
Deal volume in addiction treatment has fallen roughly 50% from its 2021 peak, depending on which advisory firm's data you use. The Braff Group tracked an 11% decline in 2024 alone. Medication-assisted treatment deals specifically—the MAT clinics providing methadone and buprenorphine—dropped 57% over a two-year period ending in 2024 compared to the prior two years. Substance use disorder treatment, which historically accounted for more than 40% of total behavioral health sector deals, is now the lagging segment while outpatient mental health and autism services have rebounded.
The contrast with non-addiction behavioral health is stark. Outpatient mental health platforms trade at 10–14 times EBITDA. Autism platforms command 12–15 times. Addiction treatment facilities? Listed assets routinely show up at 5 times EBITDA, with payer mixes that are 80–90% Medicaid and commercial reimbursement rates that haven't kept pace with cost inflation. The multiples tell you everything you need to know about how investors perceive the risk-reward profile.
Several structural factors explain the discount, and none of them are going away.
Addiction treatment has a fundamentally different reimbursement profile than other behavioral health segments, and it's not a favorable one.
The payer mix skews heavily toward Medicaid, which reimburses at rates that make sustainable margin generation difficult without significant scale. Commercial insurance coverage for substance use disorder treatment, while mandated by parity legislation and the ACA, remains inconsistent in practice. Prior authorization requirements are onerous. Length-of-stay approvals are unpredictable. Out-of-network reimbursement, which sustained the luxury residential treatment model through the mid-2010s, has been systematically squeezed as payers push toward in-network arrangements and lower-acuity settings.
The economics of methadone treatment—the most evidence-based intervention for opioid use disorder—are particularly challenging. Opioid treatment programs operate under heavy federal regulation, require daily patient visits in most cases, and generate revenue that barely covers operational costs in many markets. The regulatory structure, created under the Nixon administration when the country experienced roughly 7,000 overdose deaths annually, was never designed for a crisis of this magnitude or for the economics of modern healthcare delivery.
Value-based reimbursement, which has transformed the economics of primary care and is beginning to reshape outpatient mental health, remains embryonic in addiction treatment. By most accounts, the average SUD provider generates less than 10% of revenue from value-based arrangements. The clinical infrastructure to measure outcomes, track patients longitudinally, and demonstrate cost savings to payers simply doesn't exist at most treatment facilities. And the outcome that matters most in addiction—sustained recovery—unfolds over years, not episodes, making it poorly suited to the episodic reimbursement models that dominate the space
This is the issue that polite industry conversations tend to dance around, but investors don't: addiction treatment has a relapse problem that fundamentally complicates the investment thesis.
Relapse rates for substance use disorders range from 40–60%, broadly comparable to other chronic diseases like diabetes and hypertension. Clinicians correctly point out that relapse is a feature of the disease, not a failure of treatment. But from an investor's perspective, the implication is uncomfortable. A business where a significant percentage of your customers will need to return for additional treatment—and where that return is framed as evidence that the initial treatment didn't work—creates a narrative problem that outpatient mental health simply doesn't have.
The measurement challenge compounds this. What does success look like in addiction treatment? Thirty days of sobriety? A year? Five years? Reduced use? Harm reduction? The field itself hasn't reached consensus, and that ambiguity makes it nearly impossible to build the outcomes-based value propositions that payers and investors increasingly demand. When an autism therapy provider can show measurable improvements in adaptive behavior scores, or an outpatient mental health platform can demonstrate reductions in PHQ-9 depression scores, they're speaking the language that institutional capital understands. Addiction treatment is still searching for its equivalent.
No segment of behavioral health carries more regulatory risk or reputational baggage than addiction treatment. And the last several years have made both worse.
Acadia Healthcare, the largest standalone behavioral health company in the United States with 258 facilities, has been under sustained pressure. The DOJ investigated Acadia over admissions, length-of-stay, and billing practices, resulting in a $19.85 million False Claims Act settlement related to medically unnecessary inpatient services and compliance failures across facilities in Florida, Georgia, Michigan, and Nevada. A separate $17 million settlement resolved allegations that Acadia's West Virginia opioid treatment programs fraudulently billed Medicaid for lab testing they didn't perform. The New York Times reported that some Acadia methadone clinics fabricated therapy notes, accepted patients who weren't addicted to opioids to boost volume, and failed to provide required counseling services. The company spent $31 million on investigation-related legal costs in Q1 2025 alone, up from less than $500,000 in the same quarter the prior year.
Acadia is the most visible example, but the scrutiny extends across the sector. Senators Markey and Braun sent letters to nine private equity firms demanding answers about their OTP investments and whether profit motives were interfering with patient access to methadone. Bipartisan legislation—the Modernizing Opioid Treatment Access Act—would allow addiction medicine physicians to prescribe methadone outside of OTPs for the first time, potentially undermining the business model of every PE-backed methadone clinic in the country. PE-backed OTPs have actively opposed the legislation, a stance the senators characterized bluntly: they were maintaining a monopoly on methadone access not because it was good for patients, but because it was good for the bottom line.
For investors evaluating the space, this creates a toxic combination: a sector where the largest public company is dealing with serial fraud investigations, where Congress is actively hostile to the PE ownership model, and where proposed legislation could structurally disrupt the highest-volume treatment modality.
Every segment of behavioral health faces workforce challenges. In addiction treatment, the math is particularly grim. Demand for addiction counselors is projected to grow 3.2% annually through 2034, but supply is expected to decline by 0.8% per year, creating a projected shortage of more than 75,000 counselors—roughly 57% of the labor needed to meet demand.
The reasons are straightforward. Addiction counseling pays less than comparable roles in outpatient mental health. The work is emotionally taxing in ways that are difficult to sustain. Burnout rates are high. And the credentialing requirements, while less stringent than for licensed therapists or psychologists, still create barriers to rapid workforce expansion.
For a PE-backed platform pursuing a roll-up strategy, this workforce dynamic is devastating. You can't consolidate your way out of a labor shortage. Every acquisition brings the same staffing challenges. And unlike outpatient mental health, where telehealth has created meaningful geographic flexibility in clinician deployment, addiction treatment—particularly MAT programs requiring in-person visits—remains tied to physical locations and local labor markets.
The addiction treatment industry is simultaneously too fragmented to roll up efficiently and too diverse in its care models to standardize. The space encompasses residential treatment, partial hospitalization, intensive outpatient, traditional outpatient, medication-assisted treatment, sober living, digital therapeutics, harm reduction, and peer support—each with different economics, different regulatory requirements, different payer dynamics, and different clinical philosophies.
Payers are actively pushing toward lower-acuity outpatient settings, which has hollowed out the residential treatment model that once commanded premium reimbursement. Well-known destination treatment brands have scaled back operations as families increasingly opt for local outpatient care or telehealth alternatives. The Braff Group noted a 32% increase in deal flow for lower-cost community-based programs over a three-year period, but a corresponding decline in the higher-margin residential segment that once anchored platform valuations.
Meanwhile, the largest historical consolidator in the MAT space—BayMark Health Services—has essentially exited the acquisition market, removing a significant source of deal activity. The number of platforms that have completed more than a handful of acquisitions in the space is remarkably small. Unlike autism services, where scaled platforms with centralized operations and standardized clinical protocols can demonstrate clear synergies, addiction treatment acquisitions often bring a grab bag of care models, regulatory environments, and cultural philosophies that resist integration.
For addiction treatment to become genuinely attractive to institutional capital, several things would need to happen simultaneously—and none of them appear imminent.
Reimbursement would need to improve materially, particularly for MAT and outpatient SUD services. Commercial payers would need to reimburse at rates that reflect the actual cost of delivering evidence-based care, and Medicaid rates would need to keep pace with labor cost inflation. Given the current political environment around Medicaid—with redeterminations having already removed more than 25 million enrollees and ongoing uncertainty about work requirements and eligibility—this seems unlikely in the near term.
Outcomes measurement would need to mature. The industry needs standardized, widely accepted metrics that demonstrate the value of treatment in terms payers and investors understand: reduced emergency department utilization, lower total cost of care, sustained functional improvement. Some providers are beginning to build this infrastructure, but it remains the exception rather than the norm.
The regulatory environment would need to stabilize. The combination of active DOJ investigations, congressional scrutiny of PE ownership, and pending legislation that could disrupt the OTP business model creates a level of uncertainty that makes underwriting long-term returns extremely difficult.
And the stigma problem—both cultural and within the investment community—would need to recede. Addiction remains the behavioral health condition that carries the most social baggage. That stigma affects everything from reimbursement advocacy to community acceptance of treatment facilities to the willingness of high-performing clinicians to build careers in the space.
The addiction recovery business serves people in desperate need. The clinical work is essential, often lifesaving, and chronically underfunded. None of what follows is a comment on the importance of the mission.
But importance and investability are different things. The addiction treatment sector combines unfavorable reimbursement, unreliable outcomes metrics, severe workforce constraints, significant regulatory and legal risk, care model fragmentation, and active political hostility toward the PE ownership structure. Each of these challenges alone would give a sophisticated investor pause. Together, they create a risk profile that most institutional capital simply isn't willing to underwrite—particularly when outpatient mental health and autism services offer comparable demand dynamics with dramatically cleaner economics.
The investors who do well in addiction treatment will be the patient operators who build clinical organizations with genuine outcomes data, diversified payer relationships, and workforce strategies that go beyond paying market rates and hoping for the best. They'll be building 15-year businesses, not five-year flips. The deals will be smaller, the multiples will be lower, and the returns will depend on operational excellence rather than financial engineering.
That's a viable business. It's just not the kind of business that gets PE firms racing to deploy capital. And until the structural economics change, it won't be.
